Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry
In: ISSN: 0007-1161, 2021
academicJournal
Zugriff:
International audience ; BACKGROUND/AIMS: To compare the efficacy of ranibizumab (0.5 mg) with aflibercept (2 mg) in the treatment of cystoid macular oedema due to branch retinal vein occlusion (BRVO) over 12 months. METHODS: A multicentre, international, database observational study recruited 322 eyes initiating therapy in real-world practice over 5 years. The main outcome measure was mean change in EDTRS letter scores of visual acuity (VA). Secondary outcomes included anatomic outcomes, percentage of eyes with VA >6/12 (70 letters), number of injections and visits, time to first inactivity, switching or non-completion. RESULTS: Generalised mixed effect models demonstrated that mean (95% CI) adjusted 12-month VA changes for ranibizumab and aflibercept were similar (+10.8 (8.2 to 13.4) vs +10.9 (8.3 to 13.5) letters, respectively, p=0.59). The mean adjusted change in central subfield thickness (CST) was greater for aflibercept than ranibizumab (-170 (-153 to -187) µm vs -147 (-130 to -164) µm, respectively, p=0.001). The overall median (Q1, Q3) of 7 (4, 8) injections and 9 (7, 11) visits was similar between treatment groups. First grading of inactivity occurred sooner with aflibercept (p=0.01). Switching was more common from ranibizumab (37 eyes, 23%) than from aflibercept (17 eyes, 11%; p=0.002). CONCLUSION: Visual outcomes at 12 months in this direct comparison of ranibizumab and aflibercept for BRVO in real-world practice were generally good and similar for the 2 drugs, despite a greater effect of aflibercept on CST and time to first grading of inactivity.
Titel: |
Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry
|
---|---|
Autor/in / Beteiligte Person: | Hunt, Adrian ; Nguyen, Vuong ; Creuzot-Garcher, Catherine ; Alforja, Socorro ; Gabrielle, Pierre-Henry ; Zarranz-Ventura, Javier ; Guillemin, Martin ; Fraser-Bell, Samantha ; Casaroli Marano, Ricardo ; Arnold, Jennifer ; Mcallister, Ian ; O'Toole, Louise ; Gillies, Mark ; Barthelmes, Daniel ; Mehta, Hemal ; Hospital, Westmead ; The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia ; The University of Sydney ; Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon) ; Centre des Sciences du Goût et de l'Alimentation Dijon (CSGA) ; Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE) ; Hospital Clínic de Barcelona ; Marsden Eys Specialists ; The University of Western Australia (UWA) ; Mater Private Hospital ; Universitätsspital Zürich (USZ) ; Sydney Eye Hospital ; Moorfields Eye Hospital |
Link: | |
Zeitschrift: | ISSN: 0007-1161, 2021 |
Veröffentlichung: | HAL CCSD ; BMJ Publishing Group, 2021 |
Medientyp: | academicJournal |
DOI: | 10.1136/bjophthalmol-2020-318491 |
Schlagwort: |
|
Sonstiges: |
|